Sustained endogenous glucose production, diminished lipolysis and non-esterified fatty acid appearance and oxidation in non-obese women at high risk of type 2 diabetes.
OBJECTIVE
To evaluate early defects in glucose production, lipolysis and fatty acid oxidation in non-obese, normally glucose tolerant women, who are nevertheless at risk of type 2 diabetes.


METHODS
Ten women with previous gestational diabetes (pGDM) and ten controls were studied in two 4 h infusions of stable isotopes 6,6-(2)H(2)-glucose, 1-(13)C-palmitate, and 1,1,2,3,3-(2)H(5)-glycerol with and without infusion of adrenaline. Fatty acid oxidation was quantified using indirect calorimetry and (13)CO(2) measurements. Insulin sensitivity was evaluated using the short insulin tolerance test.


RESULTS
The pGDM and control women were non-obese and carefully matched for body mass index and fat mass. Whole body insulin sensitivity and basal insulin concentrations did not differ significantly but basal glucose concentrations were increased in women with pGDM. During a 0.9% saline infusion, glucose appearance was not significantly different at the first (90-120 min) and second (210-240 min) steady states. However, glucose appearance decreased in controls but was maintained in the pGDM women (-0.33 +/- 0.02 vs -0.03 +/- 0.08 mg/kg per min; P = 0.004). Basal glycerol appearance (0.27 +/- 0.02 vs 0.38 +/- 0.03 mg/kg per min; P = 0.02), palmitate appearance (0.74 +/- 0.09 vs 1.05 +/- 0.09 mg/kg per min; P = 0.03) and palmitate oxidation (0.07 +/- 0.01 vs 0.10 +/- 0.01 mg/kg per min; P = 0.03) were lower in the pGDM women. During the adrenaline infusion, changes in glucose, glycerol and palmitate concentrations and kinetics were similar in both groups.


CONCLUSIONS
Sustained glucose production during fasting is an early abnormality in non-obese subjects at risk of type 2 diabetes. Lipolysis and non-esterified fatty acid appearance and oxidation are diminished, suggesting an increased tendency to store fat. The observations are not readily attributable to differences in insulin or catecholamine sensitivity.
Forbes
Shareen
S
Section of Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary's Hospital, 2nd Floor, Mint Wing, Praed Street, London W2 1NY, UK. shareen.forbes@imperial.ac.uk
Robinson
Stephen
S
Dungu
Jason
J
Anyaoku
Victor
V
Bannister
Peter
P
Forster
David
D
Dissanayake
Sujata
S
McCarthy
Mark I
MI
MacDonald
Ian A
IA
Venkatesan
Soundararajan
S
Johnston
Desmond G
DG
D050154:Adiposity / Q000502:physiology; D000328:Adult; D001835:Body Weight / Q000502:physiology; D002395:Catecholamines / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004837:Epinephrine / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005947:Glucose / Q000096:biosynthesis*; D005990:Glycerol / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology; D008066:Lipolysis / Q000502:physiology*; D010084:Oxidation-Reduction; D019308:Palmitic Acid / Q000378:metabolism; D011247:Pregnancy; D012306:Risk; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D002395:Catecholamines; D005230:Fatty Acids, Nonesterified; D014662:Vasoconstrictor Agents; D019308:Palmitic Acid; D005947:Glucose; D005990:Glycerol; D004837:Epinephrine